Adapting a transforming growth factor β–related tumor protection strategy to enhance antitumor immunity
Authors:
- 1 May 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 99 (9) , 3179-3187
Abstract
Transforming growth factor β (TGF-β), a pleiotropic cytokine that regulates cell growth and differentiation, is secreted by many human tumors and markedly inhibits tumor-specific cellular immunity. Tumors can avoid the differentiating and apoptotic effects of TGF-β by expressing a nonfunctional TGF-β receptor. We have determined whether this immune evasion strategy can be manipulated to shield tumor-specific cytotoxic T lymphocytes (CTLs) from the inhibitory effects of tumor-derived TGF-β. As our model we used Epstein-Barr virus (EBV)–specific CTLs that are infused as treatment for EBV-positive Hodgkin disease but that are vulnerable to the TGF-β produced by this tumor. CTLs were transduced with a retrovirus vector expressing the dominant-negative TGF-β type II receptor HATGF-βRII-Δcyt. HATGF-βRII-Δcyt– but not green fluorescence protein (eGFP)–transduced CTLs was resistant to the antiproliferative and anticytotoxic effects of exogenous TGF-β. Additionally, receptor-transduced cells continued to secrete cytokines in response to antigenic stimulation. TGF-β receptor ligation results in phosphorylation of Smad2, and this pathway was disrupted in HATGF-βRII-Δcyt–transduced CTLs, confirming blockade of the signal transduction pathway. Long-term expression of TGF-βRII-Δcyt did not affect CTL function, phenotype, or growth characteristics. Tumor-specific CTLs expressing HATGF-βRII-Δcyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-β–secreting tumors and may be of value in treatment of these diseases.Keywords
This publication has 61 references indexed in Scilit:
- Going Mad withSmadsNew England Journal of Medicine, 1999
- Effects of TGF-β on the immune system: implications for cancer immunotherapyLeukemia, 1999
- A mechanism of repression of TGFbeta / Smad signaling by oncogenic RasGenes & Development, 1999
- The host—tumor immune conflict: from immunosuppression to resistance and destructionImmunology Today, 1997
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite InstabilityScience, 1995
- Mechanism of activation of the TGF-β receptorNature, 1994
- Differential effect of transforming growth factor β on the synthesis of Th1‐ and Th2‐like lymphokines by human T lymphocytesEuropean Journal of Immunology, 1992
- The Transforming Growth Factor-beta FamilyAnnual Review of Cell Biology, 1990
- Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.Journal of Experimental Medicine, 1987